Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment

Emulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment Emulate, Inc., the leading provider of next-generation in vitro models, today announced the publication “Integrating Liver-Chip Data into Pharmaceutical Decision-Making Processes” in Expert Opinion…

Read MoreEmulate Publishes Novel Framework to Pave the Way for the Integration of Liver-Chip Technology into Pharmaceutical Safety Assessment

Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML

Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML Daiichi Sankyo announced that quizartinib has been recommended for approval in the European Union (EU) in combination with standard cytarabine and anthracycline induction and standard…

Read MoreQuizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML

Merck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy Merck (NYSE: MRK), known as MSD outside of the United States…

Read MoreMerck Receives Positive EU CHMP Opinion for KEYTRUDA as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com

Global Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com The “Cell Freezing Media Market Size, Share & Trends Analysis Report By Product (DMSO, Glycerol), By Application (Stem Cell…

Read MoreGlobal Cell Freezing Media Market to Reach $291.3 Million by 2030 – Driven by Rising Adoption of Ready-to-Use Freezing Media – ResearchAndMarkets.com

AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months –AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a Lentiviral vector (LVV) expansion to its AGCellerate program designed to deliver…

Read MoreAGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months

Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics

Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics Biomedicines, a clinical-stage biotherapeutics company pioneering a machine-learning-powered generative biology platform, today announced that it has raised $273 million in…

Read MoreBiomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline of Preclinical and Clinical Protein Therapeutics

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment Powering AstraZeneca’s transition to net zero, the Company has agreed a 15-year partnership with Future Biogas to establish the UK’s first unsubsidised industrial-scale supply of biomethane gas, and is…

Read MoreAstraZeneca advances UK clean heat and energy efficiencies with £100m commitment

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability RS Oncology , a clinical-stage biotechnology company developing innovative therapies to eliminate mesothelioma and other diseases, was part of a…

Read MoreRS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

Takeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries

Takeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries Takeda today announces five new partnerships for its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in…

Read MoreTakeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity Ahead of discussions at the United Nations General Assembly (UNGA78), IFPMA, the association representing the research-based pharmaceutical industry, warned that…

Read MoreAhead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity